• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?

作者信息

Ballabio E, Armesto M, Breeze C E, Manterola L, Arestin M, Tramonti D, Hatton C S R, Lawrie C H

机构信息

Lymphoid Malignancy Research Group, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.

出版信息

Blood Cancer J. 2012 Aug 24;2(8):e83. doi: 10.1038/bcj.2012.31.

DOI:10.1038/bcj.2012.31
PMID:22922378
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3432485/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4523/3432485/4625b76736ed/bcj201231f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4523/3432485/4625b76736ed/bcj201231f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4523/3432485/4625b76736ed/bcj201231f1.jpg

相似文献

1
Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?硼替佐米在多发性骨髓瘤中的作用：微小RNA介导的协同作用（以及miR-27a/CDK5驱动的敏感性）？
Blood Cancer J. 2012 Aug 24;2(8):e83. doi: 10.1038/bcj.2012.31.
2
RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.药物基因组学 RNAi 筛选鉴定多发性骨髓瘤蛋白酶体抑制剂敏感性的调节剂，包括 CDK5。
Blood. 2011 Apr 7;117(14):3847-57. doi: 10.1182/blood-2010-08-304022. Epub 2011 Feb 2.
3
CDK5 inhibition in vitro and in vivo induces cell death in myeloma and overcomes the obstacle of bortezomib resistance.CDK5 抑制在骨髓瘤的体内外实验中诱导细胞死亡，并克服硼替佐米耐药的障碍。
Int J Mol Med. 2020 Jun;45(6):1661-1672. doi: 10.3892/ijmm.2020.4553. Epub 2020 Mar 26.
4
The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients.血清微小RNA表达特征在预测多发性骨髓瘤患者对硼替佐米为基础治疗的难治性中的价值
Cancers (Basel). 2020 Sep 9;12(9):2569. doi: 10.3390/cancers12092569.
5
CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma.环状 RNA ITCH 通过调节 miR-615-3p/PRKCD 轴增加硼替佐米在多发性骨髓瘤中的敏感性。
Life Sci. 2020 Dec 1;262:118506. doi: 10.1016/j.lfs.2020.118506. Epub 2020 Oct 5.
6
Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation.骨髓瘤细胞黏附于骨髓基质细胞可通过 microRNA-21 的上调而赋予其耐药性。
Leuk Lymphoma. 2011 Oct;52(10):1991-8. doi: 10.3109/10428194.2011.591004. Epub 2011 Jun 30.
7
Clinical significance of serum levels of microRNA-27a and its correlation with interleukin-10 in patients with multiple organ dysfunction syndrome caused by acute paraquat poisoning.急性百草枯中毒致多器官功能障碍综合征患者血清微小RNA-27a水平的临床意义及其与白细胞介素-10的相关性
Exp Ther Med. 2020 Mar;19(3):1961-1968. doi: 10.3892/etm.2020.8409. Epub 2020 Jan 2.
8
Protective mechanisms of microRNA-27a against oxygen-glucose deprivation-induced injuries in hippocampal neurons.微小RNA-27a对氧糖剥夺诱导的海马神经元损伤的保护机制。
Neural Regen Res. 2016 Aug;11(8):1285-92. doi: 10.4103/1673-5374.189194.
9
MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling.微小RNA-324-5p通过靶向刺猬信号通路调控多发性骨髓瘤细胞的干性、发病机制及对硼替佐米的敏感性。
Int J Cancer. 2018 Jan 1;142(1):109-120. doi: 10.1002/ijc.31041. Epub 2017 Sep 30.
10
Association of breast cancer-related microRNA polymorphisms with idiopathic primary ovarian insufficiency.乳腺癌相关微小RNA多态性与特发性原发性卵巢功能不全的关联。
Menopause. 2015 Apr;22(4):437-43. doi: 10.1097/GME.0000000000000325.

引用本文的文献

1
Dysregulation of Non-Coding RNAs: Roles of miRNAs and lncRNAs in the Pathogenesis of Multiple Myeloma.非编码RNA的失调：微小RNA和长链非编码RNA在多发性骨髓瘤发病机制中的作用
Noncoding RNA. 2023 Nov 3;9(6):68. doi: 10.3390/ncrna9060068.
2
Bortezomib Inhibits Multiple Myeloma Cells by Transactivating ATF3 to Trigger miR-135a-5p- Dependent Apoptosis.硼替佐米通过反式激活ATF3触发miR-135a-5p依赖性凋亡来抑制多发性骨髓瘤细胞。
Front Oncol. 2021 Sep 22;11:720261. doi: 10.3389/fonc.2021.720261. eCollection 2021.
3
Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma.

本文引用的文献

1
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.硼替佐米诱导的“BRCA 样”表型使多发性骨髓瘤细胞对 PARP 抑制剂敏感。
Blood. 2011 Dec 8;118(24):6368-79. doi: 10.1182/blood-2011-06-363911. Epub 2011 Sep 13.
2
miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma.miR-17-92 簇 microRNAs 赋予多发性骨髓瘤的肿瘤发生能力。
Cancer Lett. 2011 Oct 1;309(1):62-70. doi: 10.1016/j.canlet.2011.05.017. Epub 2011 Jun 12.
3
RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
微小 RNA 在诱导多发性骨髓瘤患者产生耐药性中的潜在作用。
Cells. 2021 Feb 20;10(2):448. doi: 10.3390/cells10020448.
4
Roles of miRNA dysregulation in the pathogenesis of multiple myeloma.miRNA 失调在多发性骨髓瘤发病机制中的作用。
Cancer Gene Ther. 2021 Dec;28(12):1256-1268. doi: 10.1038/s41417-020-00291-4. Epub 2021 Jan 5.
5
CDK5 inhibition in vitro and in vivo induces cell death in myeloma and overcomes the obstacle of bortezomib resistance.CDK5 抑制在骨髓瘤的体内外实验中诱导细胞死亡，并克服硼替佐米耐药的障碍。
Int J Mol Med. 2020 Jun;45(6):1661-1672. doi: 10.3892/ijmm.2020.4553. Epub 2020 Mar 26.
6
Molecular Mechanisms of Bortezomib Action: Novel Evidence for the miRNA-mRNA Interaction Involvement.硼替佐米作用的分子机制：miRNA-mRNA 相互作用参与的新证据。
Int J Mol Sci. 2020 Jan 5;21(1):350. doi: 10.3390/ijms21010350.
7
The Role and Function of microRNA in the Pathogenesis of Multiple Myeloma.微小RNA在多发性骨髓瘤发病机制中的作用与功能
Cancers (Basel). 2019 Nov 6;11(11):1738. doi: 10.3390/cancers11111738.
8
Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells.靶向 BIRC5 的 miR-101-3p 的异位表达克服多发性骨髓瘤细胞中的骨髓基质介导的耐药性。
BMC Cancer. 2019 Oct 21;19(1):975. doi: 10.1186/s12885-019-6151-x.
9
Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer.头颈癌中突变型 TP53 破坏 TP63-miR-27a* 反馈环路。
J Natl Cancer Inst. 2020 Mar 1;112(3):266-277. doi: 10.1093/jnci/djz097.
10
Cardiovascular disease-related miRNAs expression: potential role as biomarkers and effects of training exercise.心血管疾病相关的微小RNA表达：作为生物标志物的潜在作用及训练运动的影响
Oncotarget. 2018 Mar 30;9(24):17238-17254. doi: 10.18632/oncotarget.24428.
药物基因组学 RNAi 筛选鉴定多发性骨髓瘤蛋白酶体抑制剂敏感性的调节剂，包括 CDK5。
Blood. 2011 Apr 7;117(14):3847-57. doi: 10.1182/blood-2010-08-304022. Epub 2011 Feb 2.
4
Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia.下调的 miR-331-5p 和 miR-27a 与白血病的化疗耐药和复发有关。
J Cell Mol Med. 2011 Oct;15(10):2164-75. doi: 10.1111/j.1582-4934.2010.01213.x.
5
Dent's disease.丹氏病。
Orphanet J Rare Dis. 2010 Oct 14;5:28. doi: 10.1186/1750-1172-5-28.
6
Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.硼替佐米敏感性与生存素表达和 p53 状态有关，但与癌细胞类型无关。
J Exp Clin Cancer Res. 2010 Jan 22;29(1):8. doi: 10.1186/1756-9966-29-8.
7
Role of microRNA in anticancer drug resistance.微小RNA在抗癌药物耐药性中的作用。
Int J Cancer. 2010 Jan 1;126(1):2-10. doi: 10.1002/ijc.24782.
8
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.硼替佐米可诱导多发性骨髓瘤细胞中典型的核因子-κB激活。
Blood. 2009 Jul 30;114(5):1046-52. doi: 10.1182/blood-2009-01-199604. Epub 2009 May 12.
9
BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis.BAG3基因沉默使白血病细胞对硼替佐米诱导的凋亡敏感。
FEBS Lett. 2009 Jan 22;583(2):401-6. doi: 10.1016/j.febslet.2008.12.032. Epub 2008 Dec 25.
10
Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib.氧化还原稳态调节骨髓瘤细胞对硼替佐米的敏感性。
Br J Haematol. 2008 May;141(4):494-503. doi: 10.1111/j.1365-2141.2008.07066.x. Epub 2008 Mar 12.